Cytosorbents (CTSO) Accounts Payables (2010 - 2026)

Cytosorbents' Accounts Payables history runs 17 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• Quarterly Accounts Payables fell 5.82% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (down 5.82% YoY) and the FY2025 annual result came in at $2.9 million, down 14.1% from the prior year.
• Accounts Payables was $3.1 million for Q1 2026 at Cytosorbents, up from $2.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $4.8 million in Q1 2022 and bottomed at $1.7 million in Q4 2022.
• A 5-year average of $3.0 million and a median of $3.0 million in 2025 frame the typical range for Accounts Payables.
• Peak annual rise in Accounts Payables reached 187.66% in 2022, while the deepest fall reached 41.0% in 2022.
• Cytosorbents' Accounts Payables stood at $1.7 million in 2022, then jumped by 129.71% to $3.8 million in 2023, then fell by 12.16% to $3.3 million in 2024, then dropped by 14.1% to $2.9 million in 2025, then advanced by 9.17% to $3.1 million in 2026.
• Business Quant data shows CTSO's Accounts Payables at $3.1 million in Q1 2026, $2.9 million in Q4 2025, and $3.0 million in Q3 2025.